Selected original articles

Abou-Faycal C, Oszwald A, Feilen T, Contreras MJC, Schilling O, Loustau T, Steinbach F, Schachner H, Langer B, Heeringa P, Rees AJ, Orend G, Kain R. 2022. An adapted passive model of anti-MPO dependent crescentic glomerulonephritis reveals matrix dysregulation and is amenable to modulation by CXCR4 inhibition. Matrix Biol. doi: 10.1016/j.matbio.2022.01.001. PMID: 35032611

Imanaka Yoshida K*, Midwood K*, Orend G*, 2022, Editorial on special issue on Tenascins: Key Players in Tissue Homeostasis and Defense”, Front Immunol, 12, 834353. doi:10.3389/fimmu.2021.834353. 22 articles with over 61`000 views (18.5.2022).

Loustau T*, Abou-Faycal C*, Erne W*, Abel zur Wiesch P*, Ksouri A, Imhof T, Mörgelin M, Li C, Mathieu M, Salomé N, Crémel G, Dhaouadi S, Bouhaouala-Zahar B, Koch M, Orend G, Modulating tenascin-C functions by targeting the MAtrix REgulating MOtif, “MAREMO”. 2022. Matrix Biol, 108, 20-38. doi: 10.1016/j.matbio.2022.02.007. PMID: 35227929.

Orend G, Tucker RP, 2021. Did Tenascin-C Co-Evolve With the General Immune System of Vertebrates? Front Immunology, special issue on “Tenascins: Key Players in Tissue Homeostasis and Defense”, guest editors, K. Midwood, G. Orend, K. Imanaka-Yoshida. 12: 663902.

Spenlé C, Loustau T, Burckel H, Riegel G, Abou-Faycal C, Chengbei L, Yilmaz A, Petti L, Steinbach F, Ahowesso C, Jost C, Paul N, Carapito R, Noël G, Anjuère F, Salomé N, Orend G, 2021. Impact of tenascin-C on radiotherapy in a novel syngeneic oral squamous cell carcinoma model with spontaneous dissemination to the lymph nodes, Front Immunology, Special issue on “Tenascins: Key Players in Tissue Homeostasis and Defense”, guest editors, K. Midwood, G. Orend, K. Imanaka-Yoshida, published 5. 7. 2021, doi: 10.3389/fimmu.2021.636108.

Meijer M, de Vos AF, Sengers HP, Scicluna B, Roelofs J, Abou Fayçal C, Uhel F, Orend G, van der Poll T, 2021. Tenascin-C has a modest protective effect on acute lung pathology during methicillin-resistant Staphylococcus aureus-induced pneumonia in mice, Microbiology spectrum, accepted.

Murdamoothoo D, Sun Z, Yilmaz A, Deligne C, Velazquez-Quesada I, Erne W, Nascimento M, Mörgelin M, Cremel G, Paul N, Carapito R, Abou-Faycal C, Midwood K, Loustau T, Orend G, 2021. Immobilization of infiltrating cytotoxic T lymphocytes by tenascin-C and CXCL12 enhances lung metastasis, EMBO Mol Med, 13(6): e13270. Recommended by Faculty Opinions, 2% best papers in Cell biology (

Dhaouadi S, Benabderrazek R, Loustau T, Abou-Faycal C, Ksouri A, Erne W, Murdamoothoo D, Mörgelin M, Kungl A, Jung A, Ledrappier S, Benlasfar Z, Bichet S, Chiquet-Ehrismann R†, Hendaoui I, Orend G, Bouhaouala-Zahar B, 2021. Novel human tenascin-C function-blocking camel single domain nanobodies, Front Immunology, Special issue on “Tenascins: Key Players in Tissue Homeostasis and Defense”, guest editors, K. Midwood, G. Orend, K. Imanaka-Yoshida, 12:635166.

Meijer MT, de Vos AF, Scicluna BP, Roelofs JL, Abou Fayçal C, Orend G, Uhel F, van der Poll T, 2021. Tenascin-C Deficiency Is Associated With Reduced Bacterial Outgrowth During Klebsiella pneumoniae-Evoked Pneumosepsis in Mice. Front Immunology, Special issue on “Tenascins: Key Players in Tissue Homeostasis and Defense”, guest editors, K. Midwood, G. Orend, K. Imanaka-Yoshida, 12:600979.

Albacete-Albacete L, Navarro-Lérida I, López JA, Martín-Padura I, Astudillo AM, Ferrarini A, Van-der-Heyden M, Balsinde J, Orend G, Vázquez J, del Pozo MA, ECM deposition is driven by caveolin1-dependent regulation of exosomal biogenesis and cargo sorting. J Cell Biol, 219(11):e202006178.

Spenlé C*, Loustau T*, Murdamoothoo D, Erne W, Beghelli-de la Forest  Divonne S, Veber R, Petti L, Bourdely P, Mörgelin M, Brauchle EM, Cremel G, Randrianarisoa V, Camara A, Rekima S, Schaub S, Nouhen K, Imhof T, Hansen U, Paul N, Carapito R, Pythoud N, Hirschler A, Carapito C, Dumortier H, Mueller CG, Koch M, Schenke-Layland K, Kon S, Sudaka A, Anjuère F, Van Obberghen-Schilling E, Orend G. 2020. Tenascin-C orchestrates an immuno-suppressive microenvironment in oral squamous cell carcinoma, Cancer Immun Res, 8:1122-1138.

Dhaouadi S, Murdamoothoo D, Asma Tounsi A, William Erne W, Benabderrazek R, Benlasfar Z, Hendaoui L, Chiquet-Ehrismann R, Boubaker S, Orend G, Hendaoui I, Bouhaouala-Zahar B. 2020. Generation and characterization of dromedary Tenascin-C and Tenascin-W specific antibodies. Biochem Biophys Res Comm,

Deligne C, Murdamoothoo D, Gammage A, Gschwandtner M, Erne W, Loustau T, Marzeda AM, Velazquez-Quesada I, Mazzier I, Sun Z, Orend G and Midwood KS. 2020. Matrix-targeting immunotherapy controls tumor growth and spread by switching macrophage phenotype, Cancer Immun Res 8, 368 – 382.

Gamper C, Spenlé C, Boscá S, van der Heyden M, Erhardt M, Orend G, Bagnard D*, Heinlein M*, 2019, Functionalized Tobacco Mosaic Virus Coat Protein Monomers and Oligomers as Nanocarriers for Anti-Cancer Peptides, Cancers 11, 1609.

Sun Z, Velázquez-Quesada I, Murdamoothoo D, Ahowesso C, Yilmaz A, Spenlé C, Averous G, Erne W, Oberndorfer F, Oszwald A, Kain R, Bourdon C, Mangin P, Deligne C, Midwood K, Abou-Faycal C, Lefebvre O, Klein A, van der Heyden M, Chenard MP, Christofori G, Mathelin C, Loustau T, Hussenet T, Orend G*, 2019. Tenascin-C increases lung metastasis by impacting blood vessel invasions. Matrix Biol. 83, 26 – 47.

Murdamoothoo D, Schwenzer A, Kant J, Rupp T, Marzeda A, Kim Midwood K* and Orend G*, 2018, Investigating cell type specific functions of tenascin-C. Methods in Extracellular Matrix Biology. 143:401-428.

Giblin S, Murdamoothoo D, Deligne C, Schwenzer A, Orend G* and Midwood K*, 2018. How to purify and detect expression of tenascin-C. Methods in Extracellular Matrix Biology. 143:371-400.

Keklikoglou I, Kadioglu E, Bissinger S, Langlois B, Bellotti A, Orend G, Ries CH, De Palma M, 2018, Periostin limits tumor response to VEGFA inhibition, Cell Reports, 22, 2530-2540.

Mammadova-Bach E, Rupp T, Spenlé C, Jivkov I, Shankaranarayanan P, Klein A, Pisarsky L, Méchine-Neuville A, Cremel G, Kedinger M, De Wever O, Ambartsumian N, Robine S, Pencreach E, Guenot D, Goetz JG*, Simon-Assmann P, Orend G*, Lefebvre O*, 2018, Laminin α1 orchestrates VEGFA functions in the ecosystem of colorectal carcinoma, Biology of the Cell, 8, 178 – 195.

Sun Z, Schwenzer A, Rupp T, Murdamoothoo D, Lefebvre O, Klein A, Hussenet T, Orend G *. 2018, Tenascin-C promotes tumor cell migration through integrin α9β1, inhibiting YAP, Cancer Res, 78, 950-961.

Radwańska A, Grall D, Schaub S, Beghelli-de la Forest Divonne S, Ciais D, Rekima S, Rupp T, Sudaka A, Orend G, Van Obberghen-Schilling E, 2017, Counterbalancing anti-adhesive effects of Tenascin-C through fibronectin expression in endothelial cells, Scientific Reports, 7, 12762.

Midwood K*, Chiquet M, Tucker R, Orend G*, 2016, Tenascin-C at a glance. Invited contribution in the frame of the Molecule-at-a-glance series of poster reviews in J Cell Sci, 29, 4321-4327.

Rupp T, Langlois B, Radwanska A, Koczorowska MM, Sun Z, Hussenet T, Lefebvre O, Murdamoothoo D, Arnold A, Klein A, Biniossek ML, Hyenne V, Naudin E, Velazquez-Quesada I, Schilling O, Van Obberghen-Schilling E, Orend G*, 2016, Tenascin-C orchestrates glioblastoma angiogenesis by modulation of pro and anti angiogenic signaling, Cell Reports, 17, 2607-2619. IF: 8.57

Jacob L, Sawma P, Garnier N, Meyer L, Fritz J, Hussenet T, Spenlé C, Jacky Goetz J, Fernandez A, Baumlin N, Aci-Sèche S, Orend G, Roussel G, Crémel G, Genest M, Hubert P, Bagnard D, 2016. Inhibition of PlexA1-mediated brain tumor growth and tumor-associated angiogenesis using a transmembrane domain targeting peptide, Oncotarget 7, 57851-57865.

Mammadova-Bach E, Zigrino P, Brucker C, Bourdon C, Freund M, De Arcangelis A, Abrams S, Orend G, Gachet C, Mangin PH. 2016, Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell-derived ADAM9, JCI Insight. 1, e88245.

Orend G*, Oskarsson T and Chiquet-Ehrismann R, 2016, invited guest editors for the directed Issue on “Stem Cells and Matrix”, the International Journal of Biochemistry and Cell Biology, 165. doi: 10.1016/j.biocel.2016.10.012. Epub 2016 Oct 19.

Arpel A, Gamper C, Spenlé C, Fernandez A, Jacob L, Baumlin N, Laquerriere P, Orend G, Crémel G, Bagnard B, 2016. Inhibition of primary breast tumor growth and metastasis using a neuropilin-1 transmembrane domain interfering peptide, Oncotarget, 7, 54723-54732.

Tierney MT, Gromova A, Sesillo FB, Sala D, Spenlé C, Orend G, Sacco A. 2016. Autonomous extracellular matrix remodeling controls a progressive adaptation in muscle stem cell regenerative capacity during development, Cell Reports, 14, 1940-1952.

Buchert M, Rohde F, Eissmann M, Tebbutt N, Williams B, Tan CW, Owen A, Hirokawa Y, Gnann A, Orend G, Orner G, Dashwood RH, Heath JK, Ernst M, Janssen KP. 2015. A hypermorphic epithelial beta-catenin mutation facilitates intestinal tumorigenesis in mice in response to compounding WNT-pathway mutations. Dis Model Mech, 8, 1361-73.

Spenlé C, Gasser I, Saupe F, Janssen KP, Arnold C, Klein A, van der Heyden M, Mutterer J, Neuville-Méchine A, Chenard MP, Guenot D, Esposito I, Slotta-Huspenina J, Amburtsumian N, Simon-Assmann P, Orend G*. 2015. Spatial organization of the tenascin-C microenvironment in experimental and human cancer, Cell Adh Migr, 9, 4 – 13.

Midwood K* and Orend G*, 2015, Editorial for the special issue on “Tenascins: defining their roles in tissue homeostasis and cancer”, Cell Adh Migr, 9, 1 – 3.

Spenlé C, Saupe F, Midwood K, Burckel H, Noel G, Orend G*, 2015, Tenascin-C: exploitation and collateral damage in cancer management, special issue on “Tenascins: defining their roles in tissue homeostasis and cancer”, Cell Adh and Migr, 9, 141 – 153. Review.

Abada S, Lecointre A, Christine C, Ehret-Sabatier L, Saupe F, Orend G, Brasse D, Ouadi A, Hussenet T, Laquerrière P, Elhabiri M, Charbonnière LJ, 2014. Phosphonated chelates for nuclear imaging, Org Biomol Chem, 12, 9601-9620.

Chiquet-Ehrismann R+, Orend G+, Chiquet M+, Tucker RP+, Midwood KS+, 2014. Tenascins in stem cell niches, Matrix Biology, 37: 112-23. Review

Langlois B, Saupe F, Rupp T, Arnold C, Van der Heyden M, Orend G*, Hussenet T*,  2014. AngioMatrix, a gene expression signature of the tumor angiogenic switch-specific extracellular matrix, correlates with poor prognosis for human glioblastoma and colorectal cancer patients, Oncotarget, 5, 10529-10545.

Spenlé C, Lefebvre O, Lacroute J, Méchine-Neuville A, Barreau F, Blottière HM, Duclos B, Arnold C, Hussenet T,Gullberg D, Kedinger M, Sorokin L, Orend G, Simon-Assmann P,  2014. The laminin response in inflammatory bowel disease – good or evil, PLoS One, 9, e111336. Highlighted in Matrix Biology 2015, 41, 1-2.

Arpel A, Sawma P, Spenlé C, Garnier N, Velásquez-Quesada I, Hussenet T, Aci-Sèche S, Baumlin N, Duneau JP, Genest M, Brasse D, Hubert P, Crémel G, Orend G, Laquerrière P, Bagnard D, 2014. Transmembrane domain targeting peptide antagonizing ErbB2/Neu inhibits breast tumor growth and metastasis, Cell Reports, 8, 1714-1721.

Ehninger A, Boch T, Medyouf H, Mudder K, Orend G, Trumpp A, 2014. Loss of SPARC protects hematopoietic stem cells from toxicity of repeated cycles of chemotherapy by accelerating their return to quiescence. Blood, 123, 4054-4063.

Orend G*, Saupe F, Schwenzer A, Midwood KS*, 2014. The extracellular matrix and cancer: regulation of tumor cell biology by tenascin-C. iConcept Press. ISBN: 978-1-922227-25-6. Review

Saupe F, Schwenzer A, Jia Y, Gasser I, Spenlé C, Langlois B, Kammerer M, Lefebvre O, Hlushchuk R, Rupp T, Marko M, Van der Heyden M, Cremel G, Arnold C, Klein A, Simon-Assmann P, Djonov V, Neuville-Méchine A, Esposito I, Slotta-Huspenina J, Janssen K-P, de Wever O, Christofori G, Hussenet T, Orend G*, 2013. Tenascin-C downregulates Wnt inhibitor Dickkopf-1, promoting tumorigenesis in a neuroendocrine tumor model. Cell Reports 5, 482-92.

Spenlé C, Simon-Assmann P, Orend G, Miner JH, 2013,  Laminin alpha5 guides tissue patterning and organogenesis. Cell Adh Migr 7:90-100. Review.

Ritié L, Spenlé C, Lacroute J, Bolcato-Bellemin A-L, Lefebvre O, Bole-Freysot C, Jost B, Klein A, Arnold C, Kedinger M, Bagnard D, Orend G, Simon-Assmann P, 2012. Abnormal Wnt and PI3Kinase signaling in the malformed intestine of lama5 deficient mice. PLoS One, 2012, 7, e37710.

Christine C, Koubemba M, Shakir S, Clavier S, Ehret-Sabatier L, Saupe F, Orend G, Charbonnière LJ, 2012. Synthesis of an activated phosphonated bifunctional chelate with potential for PET imaging and radiotherapy. Org Biomol Chem, 10, 9183-90.

Spenlé C, Hussenet T, Lacroute J, Lefebvre O, Kedinger M, Orend G, Simon-Assmann P, 2012 Dysregulation of laminins in intestinal inflammation. Pathol Biol (Paris) 60, 41-7.

Brellier F, Martina E, Chiquet M, Ferralli J, van der Heyden M, Orend G, Schittny JC, Chiquet-Ehrismann R, Tucker RP, 2012. The adhesion modulating properties of tenascin-W. Int J Biol Sci. 8, 187-94.

Midwood K*, Hussenet T, Langlois B, Orend G*, 2011. Advances in Tenascin-C biology. Special issue on “Emerging Functions of Matricellular Proteins” in Cellular and Molecular Life Sciences (CMLS), David Roberts editor, 68, 3175-99. Review.

Simon-Assmann P, Orend G, Mammadova-Bach E, Spenlé C, Lefebvre O. 2011. Role of laminins in physiological and pathological angiogenesis. Special issue on “Angiogenesis in Development and Cancer” (Djonov V and Ribatti D; eds). Int J Develop Biol, 55, 455-465.

Schaff M, Receveur N, Bourdon C, Wurtz V, Denis CV, Orend G, Gachet C, Lanza F, Mangin PH, 2011. Novel function of tenascin-C, a matrix protein relevant to atherosclerosis, in platelet recruitment and activation under flow. Arterioscler Thromb Vasc Biol, 31, 117-124.

Van Obberghen-Schilling E*, Tucker RP, Saupe F, Gasser I, Cseh B, Orend G*, 2011. Fibronectin and tenascin-C: accomplices in vascular morphogenesis during development and tumor growth. Special issue “Angiogenesis in Development and Cancer” (Djonov V and Ribatti D; eds). Int J Develop Biol 55, 511, Review.

Heng C, Lefebvre O, Klein A, Edwards MM, Simon-Assmann P, Orend G, Bagnard D, 2011. Functional role of laminin α1 chain during cerebellum development. Cell Adh Migr, 5, 480-9.

Wang Z, Collighan RJ, Gross SR, Danen EH, Orend G, Telci D, Griffin M, 2010. RGD-independent cell adhesion via a tissue transglutaminase-fibronectin matrix promotes fibronectin fibril deposition and requires syndecan-4/2 and {alpha}5{beta}1 integrin co-signalling. J Biol Chem, 285, 40212-40229.

Edwards MM, Mammadova-Bach E, Alpy F, Klein A, Hicks WL, Roux M, Simon-Assmann P, Smith RS, Orend G, Wu J, Peachey NS, Naggert JK, Lefebvre O+, Nishina PM+, 2010. Mutations in Lama1 disrupt retinal vascular development and inner limiting membrane formation. J Biol Chem, 285, 7697-7711.

Midwood K and Orend G*, 2009. The role of tenascin-C in tissue injury and tumorigenesis. Special issue on “Matricellular proteins” J. of Cell Communication and Signaling, edited by P. Bornstein, 3, 287 – 310. Review

Midwood K, Sacre S, Inglis J, Trebaul A, Chan E, Piccinini AM, Drexler S, Sofat N, Kashiwagi M, Orend G, Brennan F and Foxwell B, 2009. Tenascin-C is an endogenous activator of TLR4 that is essential for maintaining inflammation in arthritic joint disease, Nat. Medicine,15, 774-780.

Orend G, 2008. Tenascin-C and Cancer; In: Encyclopedia of Cancer, 2nd Edition, editor: M. Schwab; Springer Verlag, October 2008, ISBN: 978-3-540-47648-1. Review.

Lange K, Kammerer M, Saupe F, Hegi ME, Grotegut S, Fluri E, Orend G*, 2008.Combined LPA/PDGF signaling triggers glioma cell migration in a tenascin-C microenvironment, Cancer Res. 68, 6942 – 52.

Degen M, Brellier F, Kain R, Ruiz C, Terracciano L, Orend G and Chiquet-Ehrismann R, 2007. Tenascin-W is a novel marker for activated tumor stroma in low-grade human breast cancer and influences cell  behavior. Cancer Res. 67, 9169- 79.

Lange K, Kammerer M, Hegi M, Grotegut S, Dittmann A, Huang W, Fluri E, Yip GW, Götte M, Ruiz C and Orend*, 2007. Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization, Cancer Res. 67, 6163-73.

Orend G* and Chiquet-Ehrismann R, 2006. Tenascin-C induced signaling in cancer, Cancer Lett. 244, 143-163. Review.

Baumann P, Cremers N, Kroese F, Orend G, Chiquet-Ehrismann R, Uede T, Yagita H and Sleeman JP, 2005. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res. 65, 10783-93.

Orend G, 2005. Potential oncogenic action of tenascin-C in tumorigenesis, International J. Biochem. and Cell Biol., 37, 1066-1083. Review.

Ruiz C, Huang W, Hegi ME, Lange K, Hamou M-F, Fluri E, Oakeley EJ, Chiquet-Ehrismann R,  Orend G*, 2004. Differential gene expression analysis reveals activation of growth promoting signaling  pathways by tenascin-C. Cancer Res.  64, 7377-85.

Orend G*, Huang W, Olayioye MA, Hynes NE, Chiquet-Ehrismann R, 2003. Tenascin-C blocks cell cycle progression of anchorage-dependent fibroblasts on fibronectin through inhibition of syndecan-4. Oncogene 22, 3917-22. Recommended by the “faculty of 1000”,

Huang W, Chiquet-Ehrismann R, Moyano JV, Garcia-Pardo A, Orend G*, 2001. Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Res 61, 8586-94. Recommended by the “faculty of 1000”,

Orend G and Chiquet-Ehrismann R, 2000. Adhesion modulation by antiadhesive molecules of the extracellular matrix. Exp. Cell Res. 261, 104-110. Review.

Pfeffer A, Schubbert R, Orend G, Hilger-Eversheim K and Doerfler W, 1999. Integrated viral genomes can be lost from adenovirus type 12-induced hamster tumor cells in a clone-specific, multistep process with retention of the oncogenic phenotype. Virus Res. 59, 113-127.

Bourdoulous S, Orend G, Pasqualini R and Ruoslahti E, 1998. Fibronectin matrix regulates activation of RHO and CDC42 GTPases and cell cycle progression. J. Cell Biol. 143, 267-276.

Orend G, Hunter T and Ruoslahti E, 1998. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p27Kip1 and p21Cip1 in anchorage-independent cells. Oncogene 16, 2575 – 2583.

Fang F+, Orend G+, Watanabe N, Hunter T and Ruoslahti E, 1996. Dependence of cyclin E-CDK2 kinase activity on cell anchorage, Science 271, 499-502. IF: 31.48

Orend G, Knoblauch M and Doerfler W, 1995. Selective loss of unmethylated segments of integrated Ad12 genomes in revertants of the Adenovirus type 12-transformed cell line T637, Virus Res. 38, 261 -267.

Doerfler W, Orend G, Schubbert R, Fechteler K, Heller H, Wilgenbus P and Schröer J, 1995. On the insertion of foreign DNA into mammalian genomes: mechanism and consequence, Gene 157, 241 –245. Review.

Orend G, Knoblauch M, Kämmer C, Tjia S, Schmitz B, Linkwitz A, Meyer zu Altenschildesche G,  Maas J and Doerfler W, 1995. The initiation of de novo methylation of foreign DNA integrated into a mammalian genome is not exclusively targeted by nucleotide sequence, J. Virol. 69, 1226 – 1242.

Orend G, Linkwitz A and Doerfler W, 1994. Selective sites of Adenovirus (foreign) DNA integration into the hamster genome: changes in integration patterns, J. Virol. 68, 187 – 194.

Orend G, Kuhlmann I and Doerfler W, 1991. The spreading of DNA methylation across integrated foreign (Adenovirus type 12) genomes in mammalian cells, J. Virol. 65, 4301 – 4308.

Doerfler W, Toth M, Kochanek S, Achten S, Freisem-Rabien U, Behn-Krappa A and Orend G, 1990. Eukaryotic DNA methylation: facts and problems, FEBS Lett. 268, 329-333. Review.